SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark to outlicense one molecule in FY10

24 Dec 2009 Evaluate

Glenmark Pharmaceuticals is looking to out-license at least one molecule in fiscal 2010, probably Melogliptin. It is renegotiating a deal for the diabetes drug and is seeking a tie-up for anti-asthma drug Oglemilast for the European market. It is also looking to outlicense phase 2-b trials Oglemilast.

 

Outlicensing of Melogliptin and launch of Crofelmer (for HIV-related diarrhoea), which is a phase 3 candidate, are focus areas for Glenmark. A successful launch of Crofelmer can add $20-25 million annually to the company's net profit.

 

Meanwhile, Glenmark expects to launch Crofelmer across the world by the end of the next fiscal. The company is expecting sales of $80 million in the next 2-3 years as it will price the product at a premium to the currently available treatment options.

crackcrack

Glenmark Pharma Share Price

2194.05 31.15 (1.44%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×